

# Levodopa Therapy in Parkinson's Disease

Mr Chaitanya Dattatray Gadge and Ms Shraddha Madan Khaladkar

Associate Professor (QAT)

Samarth Institute of Pharmacy, Belhe

**Abstract:** *Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder characterised primarily by motor dysfunction resulting from degeneration of dopaminergic neurons in the substantia nigra pars compacta. Among available therapies, levodopa remains the gold standard for symptomatic treatment of PD. Since its introduction in clinical practice, levodopa has significantly improved motor symptoms and quality of life in patients with Parkinson's disease. However, long-term therapy is associated with complications such as dyskinesias and motor fluctuations. This review paper discusses the pathophysiology of Parkinson's disease, pharmacology of levodopa, therapeutic benefits, adverse effects, long-term complications, combination therapies, recent advances, and future perspectives. The paper also highlights the importance of individualised treatment strategies to maximise efficacy and minimise complications.*

**Keywords:** Parkinson's disease, levodopa, dopamine, dyskinesia, motor fluctuations, neurodegeneration, dopamine replacement therapy

## I. INTRODUCTION

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease and affects millions of people worldwide [1]. The disease is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra, leading to dopamine deficiency in the basal ganglia [2]. Clinically, PD presents with resting tremor, bradykinesia, rigidity, and postural instability. In addition to motor symptoms, patients often experience non-motor manifestations such as depression, cognitive impairment, constipation, and sleep disorders [3].

The discovery of dopamine deficiency in the brains of patients with Parkinson's disease revolutionized treatment strategies. Levodopa (L-dopa), a precursor of dopamine, became the most effective therapy because dopamine itself cannot cross the blood-brain barrier [4]. Since the 1960s, levodopa has remained the cornerstone of PD treatment and is widely considered the most effective symptomatic therapy.

Although levodopa significantly improves motor symptoms and quality of life, long-term treatment can lead to complications including wearing-off phenomena, dyskinesias, and on-off fluctuations [5]. Therefore, careful dosing strategies and adjunctive therapies are essential for optimizing patient outcomes.

This review paper aims to provide a detailed overview of levodopa therapy in Parkinson's disease, including its pharmacology, efficacy, adverse effects, and future prospects.

## II. PARKINSON'S DISEASE: AN OVERVIEW

### 2.1 Epidemiology

Parkinson's disease affects approximately 1% of individuals over the age of 60 years [6]. The prevalence increases with age, making it one of the most common neurological disorders in the elderly population. Men are affected slightly more frequently than women.

### 2.2 Etiology

The exact cause of Parkinson's disease remains unclear. However, both genetic and environmental factors contribute to disease development. Mutations in genes such as SNCA, PARKIN, LRRK2, and PINK1 are associated with familial forms of PD [7]. Environmental risk factors include pesticide exposure, heavy metals, and head trauma.



### **2.3 Pathophysiology**

The hallmark pathological feature of PD is degeneration of dopaminergic neurons in the substantia nigra pars compacta accompanied by the presence of Lewy bodies containing alpha-synuclein [8]. Dopamine depletion disrupts normal basal ganglia circuitry, resulting in impaired motor control.

Oxidative stress, mitochondrial dysfunction, neuroinflammation, and abnormal protein aggregation contribute to neuronal degeneration [9].

## **III. HISTORICAL DEVELOPMENT OF LEVODOPA THERAPY**

Levodopa was synthesized in the early 20th century, but its therapeutic potential became evident after dopamine deficiency was identified in Parkinsonian brains [10]. In 1967, George Cotzias demonstrated dramatic clinical improvement in PD patients treated with high-dose oral levodopa [11].

Initial treatment with levodopa alone caused severe nausea, vomiting, and cardiovascular side effects due to peripheral dopamine formation. The development of peripheral decarboxylase inhibitors such as carbidopa and benserazide greatly improved treatment tolerability and effectiveness [12].

Today, levodopa remains the benchmark against which all other antiparkinsonian therapies are compared.

## **IV. PHARMACOLOGY OF LEVODOPA**

### **4.1 Mechanism of Action**

Levodopa is the metabolic precursor of dopamine. Unlike dopamine, levodopa can cross the blood-brain barrier through amino acid transport systems [13]. Inside the brain, levodopa is converted into dopamine by aromatic L-amino acid decarboxylase.

Restoration of dopamine levels improves neurotransmission in basal ganglia circuits and reduces motor symptoms.

### **4.2 Pharmacokinetics**

Levodopa is rapidly absorbed from the small intestine. Gastric emptying and dietary protein intake significantly affect absorption [14]. Large neutral amino acids compete with levodopa for transport across the intestinal mucosa and blood-brain barrier.

The plasma half-life of levodopa is approximately 60–90 minutes when administered alone.

### **4.3 Role of Carbidopa and Benserazide**

Carbidopa and benserazide inhibit peripheral decarboxylation of levodopa. Their benefits include:

Increased availability of levodopa to the brain

Reduced nausea and vomiting

Lower required doses

Reduced cardiovascular side effects

Combination therapy with levodopa/carbidopa is standard clinical practice.

## **V. CLINICAL BENEFITS OF LEVODOPA THERAPY**

### **5.1 Improvement in Motor Symptoms**

Levodopa effectively improves:

Bradykinesia

Muscle rigidity

Resting tremor

Gait disturbances

Facial expression

Among all motor symptoms, bradykinesia responds most consistently to levodopa therapy [15].



### 5.2 Improvement in Quality of Life

Levodopa significantly enhances daily functioning and independence [16]. Improved mobility enables patients to participate in social and occupational activities.

### 5.3 Diagnostic Value

A positive response to levodopa often supports the diagnosis of Parkinson's disease. Poor response may indicate atypical parkinsonian syndromes.

## VI. FORMULATIONS OF LEVODOPA

### 6.1 Immediate-Release Formulations

Immediate-release levodopa formulations provide rapid symptom relief but may produce fluctuating plasma concentrations.

### 6.2 Controlled-Release Formulations

Controlled-release preparations provide prolonged drug release and reduce dosing frequency. However, absorption variability can limit efficacy [17].

### 6.3 Levodopa-Carbidopa Intestinal Gel

Levodopa-carbidopa intestinal gel (LCIG) delivers continuous medication directly into the jejunum via infusion pumps. This method improves symptom control in advanced PD [18].

### 6.4 Inhaled Levodopa

Inhaled levodopa provides rapid relief during sudden "off" periods by bypassing gastrointestinal absorption.

## VII. ADVERSE EFFECTS OF LEVODOPA

### 7.1 Gastrointestinal Effects

Common gastrointestinal side effects include:

Nausea

Vomiting

Loss of appetite

These effects are mainly due to peripheral dopamine formation.

### 7.2 Cardiovascular Effects

Orthostatic hypotension and arrhythmias may occur, especially in elderly patients.

### 7.3 Neuropsychiatric Effects

Hallucinations, confusion, anxiety, insomnia, and psychosis are observed in some patients receiving chronic therapy [19].

### 7.4 Dyskinesias

Levodopa-induced dyskinesias are involuntary, abnormal movements associated with long-term therapy.

## VIII. MOTOR COMPLICATIONS OF LONG-TERM THERAPY

### 8.1 Wearing-Off Phenomenon

Wearing off refers to the reappearance of symptoms before the next scheduled dose.



### 8.2 On-Off Fluctuations

Patients may alternate unpredictably between mobile (“on”) and immobile (“off”) states.

### 8.3 Dyskinesias

Dyskinesias are linked to pulsatile dopamine receptor stimulation and disease progression [20].

#### Types of Dyskinesias

Peak-dose dyskinesia

Diphasic dyskinesia

Off-period dystonia

### 8.4 Risk Factors

Risk factors include:

Younger age at disease onset

High levodopa doses

Long duration of treatment

## IX. MANAGEMENT OF MOTOR COMPLICATIONS

Strategies to reduce complications include:

- Dose fractionation
- Controlled-release formulations
- Addition of dopamine agonists
- COMT inhibitors
- MAO-B inhibitors
- Deep brain stimulation

Continuous dopaminergic stimulation is considered an effective strategy for minimizing motor complications.

## X. COMBINATION THERAPY

### 10.1 Dopamine Agonists

Drugs such as pramipexole and ropinirole directly stimulate dopamine receptors and may reduce levodopa requirements.

### 10.2 COMT Inhibitors

Entacapone and tolcapone prolong levodopa action by inhibiting catechol-O-methyltransferase.

### 10.3 MAO-B Inhibitors

Selegiline and rasagiline reduce dopamine breakdown in the brain.

### 10.4 Amantadine

Amantadine is effective in reducing levodopa-induced dyskinesias.

## XI. LEVODOPA IN EARLY PARKINSON’S DISEASE

There has been debate regarding whether levodopa should be delayed in early disease due to concerns about dyskinesia development. However, evidence suggests that improved quality of life outweighs these concerns [21].

Early treatment may improve functional independence and mobility.



## **XII. LEVODOPA IN ADVANCED PARKINSON'S DISEASE**

In advanced PD, levodopa remains essential despite increased complications. Continuous infusion therapies and surgical interventions such as deep brain stimulation are often required.

Advanced disease management focuses on balancing symptomatic control with adverse effects.

## **XIII. SPECIAL CONSIDERATIONS**

### **13.1 Elderly Patients**

Elderly individuals are more prone to confusion and hallucinations. Lower doses and careful titration are recommended.

### **13.2 Dietary Protein Interaction**

Protein-rich meals interfere with levodopa absorption due to competition with amino acid transporters.

### **13.3 Drug Interactions**

Dopamine-blocking drugs such as antipsychotics may worsen Parkinsonian symptoms.

## **XIV. RECENT ADVANCES IN LEVODOPA THERAPY**

### **14.1 Extended-Release Preparations**

Newer extended-release formulations provide more stable plasma concentrations and reduce motor fluctuations.

### **14.2 Continuous Dopaminergic Stimulation**

Research focuses on achieving continuous stimulation to prevent pulsatile receptor activation.

### **14.3 Nanotechnology-Based Delivery**

Nanocarriers and transdermal delivery systems are under investigation to improve bioavailability and reduce adverse effects.

### **14.4 Gene Therapy**

Gene therapy aims to restore dopaminergic function and may complement levodopa therapy in the future.

## **XV. FUTURE PERSPECTIVES**

Future developments in levodopa therapy include:

Personalized medicine

Biomarker-guided treatment

Neuroprotective agents

Stem cell therapy

Improved drug delivery systems

Digital monitoring technologies and artificial intelligence may further optimize treatment strategies.

## **XVI. CONCLUSION**

Levodopa remains the most effective symptomatic treatment for Parkinson's disease and has dramatically improved patient quality of life since its introduction. Despite the development of newer therapies, levodopa continues to be the gold standard for managing motor symptoms.

Long-term use is associated with complications such as dyskinesias and motor fluctuations, necessitating individualized treatment approaches. Advances in pharmaceutical formulations, infusion systems, and adjunctive therapies have improved treatment outcomes.



Future research should focus on disease-modifying therapies and strategies that provide continuous dopaminergic stimulation while minimizing adverse effects. Nevertheless, levodopa is expected to remain central to Parkinson's disease management for many years.

#### REFERENCES

- [1]. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. *Nature Reviews Disease Primers*. 2017;3:17013.
- [2]. Kalia LV, Lang AE. Parkinson's disease. *Lancet*. 2015;386(9996):896-912.
- [3]. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease. *Lancet Neurology*. 2006;5(3):235-245.
- [4]. Hornykiewicz O. Dopamine and Parkinson's disease. *Neurology*. 1998;51:S2-S9.
- [5]. Ahlskog JE, Muentner MD. Frequency of levodopa-related dyskinesias. *Movement Disorders*. 2001;16(3):448-458.
- [6]. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. *Lancet Neurology*. 2006;5(6):525-535.
- [7]. Klein C, Westenberger A. Genetics of Parkinson's disease. *Cold Spring Harbor Perspectives in Medicine*. 2012;2(1):a008888.
- [8]. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. *Nature*. 1997;388(6645):839-840.
- [9]. Dexter DT, Jenner P. Parkinson disease: molecular mechanisms. *Free Radical Biology and Medicine*. 2013;62:132-144.
- [10]. Birkmayer W, Hornykiewicz O. The effect of L-dopa on Parkinsonism. *Wien Klin Wochenschr*. 1961;73:787-788.
- [11]. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of Parkinsonism. *New England Journal of Medicine*. 1967;276(7):374-379.
- [12]. Fahn S. History of levodopa therapy. *Movement Disorders*. 2008;23:S497-S508.
- [13]. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine receptor stimulation. *Trends in Neurosciences*. 2000;23:S117-S126.
- [14]. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. *Clinical Neuropharmacology*. 1984;7(1):35-49.
- [15]. Marsden CD, Parkes JD. Long-term levodopa therapy. *Lancet*. 1977;1(8007):345-349.
- [16]. Schrag A, Jahanshahi M, Quinn N. Quality of life in Parkinson's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2000;69(3):308-312.
- [17]. Hauser RA. Levodopa: past, present, and future. *European Neurology*. 2009;62(1):1-8.
- [18]. Olanow CW, Kieburtz K, Odin P, et al. Intrajejunal infusion of levodopa-carbidopa intestinal gel. *Lancet Neurology*. 2014;13(2):141-149.
- [19]. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease. *Brain*. 2000;123(4):733-745.
- [20]. Cenci MA, Lundblad M. L-dopa-induced dyskinesia. *Journal of Neurochemistry*. 2006;99(2):381-392.

